Showing papers by "Arnon D. Cohen published in 1994"

Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels

Abstract: Immunosuppressive acidic protein (IAP) has been described as a tumor marker in a number of malignant diseases. To evaluate the clinical importance of IAP in breast cancer patients, IAP serum level was determined in 75 breast cancer patients, using single radial immunodiffusion. Serum samples were also tested for CA 15-3. Cut off value for IAP was determined according to IAP serum level in 50 patients with benign, non inflammatory, diseases, and was set as 725 microgram/ml. Mean IAP serum level (623 mcg/ml) and positivity rate (20%) in 24 breast cancer patients with active disease were similar to those in 51 breast cancer patients with no evidence of disease (590 mcg/ml and 18%). The mean CA 15-3 serum level and positivity rate were significantly higher in patients with active disease (200 units/ml, 67%), compared to patients with no evidence of disease (18.3 units/ml, 6%). In our experience IAP was not found to be an effective tumor marker in breast cancer.

CA 125 in diagnosis and prognosis of epithelial ovarian cancer

Abstract: In 59 women with epithelial ovarian cancer serum CA 125 was determined and they were then followed for 3 years. In those with active disease, mean serum CA 125 (289 units/ml) and positivity rate (85%) were significantly higher than in those without evidence of disease (44 units/ml and 17%, p = 0.001 and p < 0.001, respectively). Actuarial 3-year survival curves were calculated according to CA 125 serum level. 91% of those with CA 125 lower than 35 units/ml survived 3 years, as compared to 40% of those with CA 125 levels higher than 35 units/ml (p < 0.01). In ovarian cancer CA 125 serum level correlates with the state of the disease and can be used in the prediction of 3-year survival.